Scientist Behind COVID-19 mRNA Vaccine Says Her Team's Next Target Is Cancer

An anonymous reader quotes a report from CBC.ca: The scientist who won the race to deliver the first widely used coronavirus vaccine says people can rest assured the shots are safe, and that the technology behind it will soon be used to fight another global scourge -- cancer. Ozlem Tureci, who founded the German company BioNTech with her husband, Ugur Sahin, was working on a way to harness the body's immune system to tackle tumors when they learned last year of an unknown virus infecting people in China. Over breakfast, the couple decided to apply the technology they'd been researching for two decades to the new threat. Britain authorized BioNTech's mRNA vaccine for use in December, followed a week later by Canada. Dozens of other countries, including the U.S., have followed suit and tens of millions of people worldwide have since received the shot developed together with U.S. pharmaceutical giant Pfizer. [...] As BioNTech's profile has grown during the pandemic, so has its value, adding much-needed funds the company will be able to use to pursue its original goal of developing a new tool against cancer. The vaccine made by BioNTech-Pfizer and U.S. rival Moderna uses messenger RNA, or mRNA, to carry instructions into the human body for making proteins that prime it to attack a specific virus. The same principle can be applied to get the immune system to take on tumors. "We have several different cancer vaccines based on mRNA," said Tureci. Asked when such a therapy might be available, Tureci said "that's very difficult to predict in innovative development. But we expect that within only a couple of years, we will also have our vaccines [against] cancer at a place where we can offer them to people." For now, Tureci and Sahin are trying to ensure the vaccines governments have ordered are delivered and that the shots respond effectively to any new mutation in the virus.

Read more of this story at Slashdot.

from Slashdot https://ift.tt/2OU36sN

Share on FacebookPlus on Google+

SUBSCRIBE TO OUR NEWSLETTER